T he weight-loss drug Zepbound (tirzepatide) now has another major benefit: on Dec. 20, it became the first drug approved by ...

The FDA on Friday approved Eli Lilly's weight-loss drug Zepbound as a treatment for moderate-to-severe sleep apnea and ...

Obstructive sleep apnea is a sleep disorder that causes your breathing to stop and start during the night. This can lead to loud snoring, disrupted rest and daytime fatigue, among other symptoms.

If you have sleep apnea and obesity, tirzepatide Zepbound may offer relief and support weight loss. Ask your doctor if it’s a ...

The approval was based on the results of the SURMOUNT-OSA trial, which found patients had fewer breathing disruptions.

The US Food and Drug Administration approved a new indication for Eli Lilly’s formulation of tirzepatide to treat moderate to ...

The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with ...

The Food and Drug Administration has approved Zepbound to treat obstructive sleep apnea for people who are moderately or ...

This weight-loss drug, designed for obese patients, significantly reduces breathing disruptions and offers a new treatment ...

“Today’s approval marks the first drug treatment option for certain patients with obstructive sleep apnea,” said Sally ...